NCT02575079

Parafilm to Prevent CLABSI in Pediatric Patients Undergoing HCT

Parafilm Application to Prevent Central Line Associated Bloodstream Infections in Pediatric Patients Undergoing Hematopoietic Cell Transplantation

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 119 (actual)
• Sponsor: Emory University · Academic / Other
• Sex: All
• Age: 21 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to see if applying parafilm as an external barrier on the central line in children having a bone marrow transplant helps to prevent central line associated bloodstream infection(s) and also to assess the ease of use of parafilm.

Detailed description

Central line associated bloodstream infections (CLABSI) result in significant morbidity and mortality, particularly in patients undergoing hematopoietic cell transplantation (HCT). HCT patients are at high risk for CLABSI due to multiple factors, including prolonged immune suppression and the need for long-term central venous access. The investigators want to assess the feasibility of the use of a parafilm central line barrier (parafilm) as standard of care in pediatric HCT patients. The investigators will also assess the effectiveness of the parafilm to reduce the incidence of CLABSI in these patients.

Conditions

• Central Line Associated Bloodstream Infections (CLABSI)
• Bone Marrow Transplant

Interventions

Type	Name	Description
DEVICE	Parafilm	Single-use, pre-cut sections of parafilm over the central venous catheter (CVC) hub (if not connected) or around the CVC hub connection (if connected). Parafilm will be maintained on the CVC until it is removed.

Timeline

• Start date: 2015-03-01
• Primary completion: 2018-03-29
• Completion: 2018-03-29
• First posted: 2015-10-14
• Last updated: 2019-06-25
• Results posted: 2019-06-25

Locations

1 site across 1 country: United States